Engage Debtco

Engage Therapeutics was a clinical-stage biopharmaceutical company focused on developing Staccato Alprazolam (now marketed as VALTOCO or similar rescue therapies in the class) for the rapid termination of active epileptic seizures. The company's lead product candidate utilized a hand-held, breath-actuated inhaler to deliver a proprietary formulation of alprazolam into the deep lung for rapid systemic absorption. This delivery method was designed to provide a non-invasive alternative to existing rescue treatments like rectal gels or nasal sprays. In 2020, the company was acquired by UCB, which integrated the technology into its epilepsy portfolio to address the needs of patients experiencing seizure clusters.